GLPwatch
Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures.
J Diabetes Complications · 2024
Last updated 2026-05-28In a study of people with type 2 diabetes, those who took 20 micrograms of lixisenatide daily for 8 weeks had much slower emptying of a liquid glucose drink compared to those given a placebo. After 240 minutes, 2% of the drink remained in the stomach for the lixisenatide group, while 48% remained for the placebo group.
AI summary of the abstract below.
| Journal | J Diabetes Complications, 2024 |
|---|---|
| Citations | 8 |
| Relative citation ratio | 1.80 |
| NIH percentile | 70 |
| Molecules | lixisenatide |
| Conditions studied | Type 2 Diabetes, Gastroparesis |
Abstract
Gastric emptying of a glucose drink was measured in people with type 2 diabetes given lixisenatide (20 μg/day or placebo) for 8 weeks. Intragastric retention at 240 min (2 (0-11)% vs 48 (3-97)%; P < 0.0001) was much greater with lixisenatide than placebo. Accordingly, lixisenatide may delay liquid gastric emptying markedly.
Verbatim abstract via PubMed 38870730 ↗
Related research
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
- Trial of Lixisenatide in Early Parkinson's Disease.
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.